Cardiac, renal, and metabolic effects of sodium–glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium–glucose co-transporter 2 inhibitors

Cardiac, renal, and metabolic effects of sodium–glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium–glucose co-transporter 2 inhibitors

In 2015, the first large-scale placebo-controlled trial designed to assess cardiovascular safety of glucose-lowering with sodium–glucose co-transporter 2 (SGLT2) inhibition in type 2 diabetes mellitus raised hypotheses that the class could favourably modify not only risk of atherosclerotic cardiovas...

書誌詳細
主要な著者:	Herrington, WG, Savarese, G, Haynes, R, Marx, N, Mellbin, L, Lund, LH, Dendale, P, Seferovic, P, Rosano, G, Staplin, N, Baigent, C, Cosentino, F
フォーマット:	Journal article
言語:	English
出版事項:	Wiley 2021

類似資料

Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice
著者:: Giuseppe Rosano, 等
出版事項: (2020-11-01)

Effect of sodium-glucose Co-transporter 2 inhibitors on coronary microcirculation
著者:: Shaoxin Chen, 等
出版事項: (2025-02-01)

Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors
著者:: Moran Gvili Perelman, 等
出版事項: (2024-01-01)

Impact of diabetes on the effects of sodium glucose co-transporter-2 (SGLT2) inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
著者:: Herrington, W, 等
出版事項: (2022)

Current developments in peritoneal glucose transport and sodium-glucose co-transporter 2 inhibitors during peritoneal dialysis
著者:: Fan Yang, 等
出版事項: (2023-11-01)

Efficacy of sodium-glucose co-transporter-2 inhibitors in patients with heart failure
著者:: E. V. Kovalenko, 等
出版事項: (2021-02-01)

The effect of sodium-glucose co-transporter-2 inhibitors on markers of subclinical atherosclerosis
著者:: Panagiotis Stachteas, 等
出版事項: (2023-12-01)

Sodium-glucose co-transporter-2 inhibitor-associated non-diabetic ketoacidosis: a case report
著者:: Vincenzo Trapanese, 等
出版事項: (2024-04-01)

Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials
著者:: Staplin, N, 等
出版事項: (2021)

Impact of Sodium‐Glucose Co‐Transporter‐2 Inhibitors on Exercise‐Induced Pulmonary Hypertension
著者:: Taijyu Satoh, 等
出版事項: (2024-10-01)

Myeloproliferative Neoplasms and Sodium-Glucose Co-Transporter-2 Inhibitors: A Case Series
著者:: Pusem Patır, 等
出版事項: (2024-06-01)

Advances in sodium-glucose transporter protein 2 inhibitors and tumors
著者:: Jiaqi Wang, 等
出版事項: (2025-02-01)

The effect of sodium‐glucose co‐transporter 2 inhibitors on outcomes after cardiac resynchronization therapy
著者:: Bray, JJ, 等
出版事項: (2024)

The effect of sodium‐glucose co‐transporter 2 inhibitors on outcomes after cardiac resynchronization therapy
著者:: Jonathan J.H. Bray, 等
出版事項: (2024-08-01)

Individual Approach to Prescribing Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Hypertrophic Cardiomyopathy
著者:: Vira Y. Tseluyko, 等
出版事項: (2024-03-01)

Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials
著者:: Vale, C, 等
出版事項: (2024)

Sodium-glucose co-transporter-2 inhibitor cardiovascular outcome trials and generalizability to English primary care
著者:: Hinton, W, 等
出版事項: (2020)

Effects of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes in women versus men
著者:: Rådholm, K, 等
出版事項: (2019)

Effects of Sodium–Glucose Co-Transporter 2 Inhibitors on Serum Chloride Concentrations in Patients with Heart Failure
著者:: Ivana Jurin, 等
出版事項: (2024-11-01)

Metabolic reprogramming as the basis for sodium-glucose co-transporter type 2 inhibitors cardio- and nephroprotective effect
著者:: O N. Kurochkina, 等
出版事項: (2024-06-01)

Real-world effectiveness and safety of sodium-glucose co-transporter 2 inhibitors in chronic kidney disease
著者:: Supattra Hunsuwan, 等
出版事項: (2025-01-01)

Sodium-glucose co-transporter-2 inhibitors in heart failure and chronic kidney disease: the role of empagliflozin
著者:: M. M. Batyushin
出版事項: (2021-04-01)

Sodium-glucose co-transporter 2 inhibitors: a pleiotropic drug in humans with promising results in cats
著者:: Aline B. Vieira, 等
出版事項: (2025-02-01)

The clinical cases of ketoacidosis in patients with 2 type diabetes treated with inhibitors of sodium-glucose co-transporter
著者:: Diana Sh. Avzaletdinova, 等
出版事項: (2021-09-01)

Sodium-Glucose Linked Transporter-2 Inhibitors in Chronic Kidney Disease
著者:: L. Zanoli, 等
出版事項: (2015-01-01)

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
著者:: Herrington, W, 等
出版事項: (2018)

Sodium-glucose co-transporter 2 (SGLT2) inhibitor: comparing trial data and real-world use
著者:: McGovern, A, 等
出版事項: (2017)

Incidental changes in hemoglobin levels in patients with myelofibrosis receiving treatment with sodium-glucose co-transporter-2 inhibitors
著者:: Fnu Aperna, 等
出版事項: (2024-11-01)

Sodium glucose co-transporter 2 inhibitors (SGLT2i) for pediatric kidney disease: the future is near
著者:: Gilda M. Portalatin, 等
出版事項: (2025-01-01)

Benefit and Safety of Sodium-Glucose Co-Transporter 2 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
著者:: Ja Young Jeon, 等
出版事項: (2024-09-01)

Sodium–glucose co-transporter-2 inhibitors - empagliflozin and dapagliflozin as future therapy for Alport Syndrome, literature review
著者:: Magdalena Kłusek, 等
出版事項: (2024-07-01)

Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors in Heart Failure: A Comprehensive Review of Literature
著者:: Asfandyar Khattak, 等
出版事項: (2024-04-01)

The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis
著者:: Muhammad Usman Ali, 等
出版事項: (2024-02-01)

Sodium-Glucose Transport Protein 2 Inhibitors Association with Euglycemic Diabetic Ketoacidosis
著者:: Caroline Wojtas, 等
出版事項: (2023-01-01)

Sodium–Glucose Transporter 2 Inhibitors in Heart Failure: An Overview of Systematic Reviews
著者:: Yixuan Fang, 等
出版事項: (2024-06-01)

Effects of sodium-glucose cotransporter 2 inhibitors on cause-specific cardiovascular death in patients with CKD
著者:: Fletcher, RA, 等
出版事項: (2024)

Sodium-glucose co-transporter-2 (SGLT2) inhibitors: comparing trial and real world use (study protocol)
著者:: McGovern, A, 等
出版事項: (2017)

When Should We Start Sodium–Glucose Co-transporter Inhibitors in Patients with Heart Failure? The Importance of Early Intervention
著者:: Moritake Iguchi, 等
出版事項: (2023-06-01)

A New Chapter in the Treatment of Patients with Heart Failure. The Role of Sodium-Glucose Co-transporter Type 2 Inhibitors
著者:: D. P. Golubovskaya, 等
出版事項: (2022-11-01)

Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
著者:: Kris Aubrey-Bassler, 等
出版事項: (2019-02-01)